Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) were up 3.1% on Monday . The company traded as high as $136.26 and last traded at $136.18, with a volume of 679,444 shares. The stock had previously closed at $132.13.

A number of analysts have recently weighed in on ALXN shares. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Friday, June 17th. Piper Jaffray Cos. restated an “overweight” rating and issued a $185.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, August 16th. Jefferies Group restated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Sunday, May 29th. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $221.00 target price (down from $228.00) on shares of Alexion Pharmaceuticals in a report on Tuesday, June 7th. Finally, SunTrust Banks Inc. reduced their target price on shares of Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating on the stock in a report on Wednesday, July 13th. Seven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $182.98.

The company’s 50 day moving average is $129.09 and its 200-day moving average is $138.02. The firm has a market capitalization of $30.53 billion and a price-to-earnings ratio of 342.06.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the consensus estimate of $1.17 by $0.04. The company had revenue of $753 million for the quarter, compared to analyst estimates of $743.18 million. During the same quarter in the previous year, the company earned $1.44 EPS. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. Equities research analysts expect that Alexion Pharmaceuticals Inc. will post $4.65 earnings per share for the current year.

In related news, Director Leonard Bell sold 1,010 shares of the business’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $138,511.40. Following the sale, the director now directly owns 405,289 shares in the company, valued at approximately $55,581,333.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP John B. Moriarty sold 918 shares of the business’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the completion of the sale, the executive vice president now owns 51,360 shares in the company, valued at $6,970,579.20. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its stake in Alexion Pharmaceuticals by 563.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 113,751 shares of the biopharmaceutical company’s stock valued at $21,698,000 after buying an additional 96,615 shares in the last quarter. Calvert Investment Management Inc. increased its position in shares of Alexion Pharmaceuticals by 21.7% in the fourth quarter. Calvert Investment Management Inc. now owns 10,051 shares of the biopharmaceutical company’s stock valued at $1,917,000 after buying an additional 1,790 shares during the last quarter. American International Group Inc. increased its position in shares of Alexion Pharmaceuticals by 1.2% in the fourth quarter. American International Group Inc. now owns 98,141 shares of the biopharmaceutical company’s stock valued at $18,720,000 after buying an additional 1,203 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Alexion Pharmaceuticals by 5.4% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 578,446 shares of the biopharmaceutical company’s stock valued at $110,339,000 after buying an additional 29,410 shares during the last quarter. Finally, I.G. Investment Management LTD. increased its position in shares of Alexion Pharmaceuticals by 4.6% in the fourth quarter. I.G. Investment Management LTD. now owns 31,750 shares of the biopharmaceutical company’s stock valued at $6,056,000 after buying an additional 1,410 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.